Sinopec Choose TruScreen for Employee Screening Program

Sinopec Choose TruScreen for Employee Screening Program

By Fleur Revell
11 June 2015

TruScreen Limited (NZAX: TRU), a New Zealand company with a unique real time cervical cancer screening technology, has announced that it has been selected by Sinopec, one of China’s largest oil and petroleum products producers, to screen its female employees in the Shengli Oil Fields, Shandong Province, the Peoples Republic of China.

The program aims to screen 130,000 women between now and December 2016, and is a joint initiative between the Sinopec Shengli Oil Field, Beijing SiweiXiangtai Tech Co Ltd (a principal distributor of TruScreen’s products in China), and TruScreen.

Sinopec Shengli Oil Field will purchase TruSceen’s disposable Single Use Sensors (SUS) from Beijing SiweiXiangtai Tech Co Ltd, and both Beijing SiweiXiangtai Tech Co Ltd and TruScreen will provide training and clinical support for the program.

The program is scheduled to be conducted in three phases:

Phase 1: The establishment of protocols and the training of clinicians.
Phase 2: The screening of eligible employees and family members of the Shengli Oil Field. Phase 3: The screening of eligible residents of Dongying City, the city near to where the oil
fields are located.

TruScreen has received an order from Beijing SiweiXiangtai Tech Co Ltd for the first 8,100 SUS (NZ$74,000 value) to be used in the programme.

The full commercial value of the program to TruScreen, if the target of 130,000 women is achieved, would be approximately NZ$1,100,000 in total SUS sales.

The Sinopec program follows the recent announcement of the start of a program with the China Doctors Association which aims to screen 100,000 women by the end of 2016, and closely follows TruScreen’s gaining of China Food and Drug Administration (CFDA) regulatory approval on April
30, 2015.

TruScreen will continue to focus on China and is working with its distribution partners to develop further networks of similar screening programmes.

TruScreen CEO Martin Dillon estimates the Chinese cervical cancer screening market to be worth an estimated NZ$1bn per annum.

ends

© Scoop Media